Implantable cardioverter‐defibrillator in Brugada syndrome: Long‐term follow‐up
| Autor: | Gretje Roterberg, Siegfried Lang, Ibrahim El-Battrawy, Martin Borggrefe, Uzair Ansari, Volker Liebe, Ibrahim Akin, Xiaobo Zhou |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Time Factors complications medicine.medical_treatment Perforation (oil well) Clinical Investigations 030204 cardiovascular system & hematology Global Health Pericardial effusion Sudden cardiac death 03 medical and health sciences Electrocardiography 0302 clinical medicine Internal medicine medicine Endocarditis Humans 030212 general & internal medicine Brugada syndrome Brugada Syndrome business.industry Brugada Sotalol General Medicine medicine.disease Implantable cardioverter-defibrillator Defibrillators Implantable Survival Rate Death Sudden Cardiac Pneumothorax Cardiology outcome Cardiology and Cardiovascular Medicine business devices medicine.drug Follow-Up Studies |
| Zdroj: | Clinical Cardiology |
| ISSN: | 1932-8737 0160-9289 |
| Popis: | Background Brugada syndrome (BrS) is associated with sudden cardiac death (SCD). Although implantable cardioverter-defibrillator (ICD) implantation is recommended, the long-term outcomes and follow-up data with regard to ICD complications have led to controversy. Hypothesis In the present study, we described the data assimilated in a total of 11 studies, analyzing the outcome in 747 BrS patients receiving ICD. Methods Data were performed and analyzed after a systematic review of literature compiled from a thorough database search (PubMed, Web of Science, Cochrane Library, and Cinahl). Results The mean age of patients receiving ICD was (43.1 ± 13.4, 82.5% males, 46.6% spontaneous BrS type I). Around 15.3% of the patients were admitted due to SCD and 10.4% suffered from atrial arrhythmia. Appropriate shocks were documented in 18.1% of the patients over a mean follow-up period of 82.3 months (47.5-110.4). The following complications were recorded: lead failure and fracture (5.4%), lead perforation (0.7%), lead dislodgement (1.7%), infection (3.9%), pain (0.4%), subclavian vein thrombosis (0.3%), pericardial effusion (0.1%), endocarditis (0.1%), psychiatric problems (1.5%), pneumothorax (0.7%). Inappropriate shocks were documented in 18.1% of the patients. The management of inappropriate shocks was achieved by pulmonary vein isolation (0.5%), drug treatment with sotalol (1.3%) or sotalol with beta-blocker (0.3%) and hydroquinidine (0.1%). Conclusions ICD therapy in BrS is associated with relevant ICD-related complications including a substantial risk of inappropriate shocks more frequently in symptomatic BrS patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text